Sanofi (SNY.US) initiates clinical trials for TSLP/IL-13 dual antibodies for COPD II/III.

According to the Wise Finance APP, on September 24th, the global clinical trial registry website showed that Sanofi's TSLP/IL-13 dual-antibody Lunsekimig (SAR443765) has progressed to the II/III phase and has initiated two II/III phase clinical trials (THESEUS and PERSEPHONE) targeting chronic obstructive pulmonary disease (COPD).